DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ksrvdz/investigation) has announced the addition of the "Investigation Report on China's Nifedipine Market, 2010-2019" report to their offering.
The synthesis of nifedipin by Bayer researchers in 1966 opened a new chapter in the treatment of cardiovascular diseases. Developed by Bayer in 1992, nifedipin controlled release tablet (Adalat) has given a new life to nifedipin and created a new dose of hypertension drug. So far, Adalat has benefited hundreds of millions of hypertension patients that include Chinese ones ever since it entered China in 1994.
Nifedipin developed fast after entering China with sales value exceeding 300 million since 2010 and 4 million in 2014. And Bayer (Germany) dominated the market with a share of over 92% in 2014 which still keeps growing. However, Bayer's market share for sales volume was only about 60% due to its high price. Against the background that more and more people are suffering from cardiovascular diseases at a younger age, nifedipine will enjoy a vast market. And local enterprises can make use of price advantage and enhance R&D so as to take up a share in the market.
Key Topics Covered:
1 Related Concepts of Nifedipine
2 Market Profile of Nifedipine in China
3 Survey on Nifedipine Sales in China, 2010-2014
4 Survey on Market Share of Major Nifedipine Manufacturers in China, 2010-2014
5 Survey on Dosage Forms of Nifedipine in China, 2010-2014
6 Reference Price of Nifedipine in Chinese Hospitals in 2014
7 Major Manufacturers of Nifedipine in Chinese Market, 2010-2014
8 Market Outlook of Nifedipine in China, 2015-2019
- China National Pharmaceutical Industry Corporation Ltd
- Guangdong Medi-world Pharmacy Co. Ltd.
- Jiangsu Haici Biological Pharmaceutical Co., Ltd
- Shanghai Shyndec Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/ksrvdz/investigation